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Summary A retrospective case note study of the aetiology and course of children in
convulsive status epilepticus (CSE) admitted to a large paediatric intensive care unit
(PICU) was undertaken between January 1999 and April 2004. Status epilepticus was
defined as a prolonged (>30 min) tonic—clonic seizure irrespective of whether the
seizure had stopped prior to admission to PICU. During this period, 137 (74 male)
children aged 1 month to 15 years were admitted to PICU with 147 episodes of status
epilepticus. Forty-seven of the 137 children (34%) were admitted following a pro-
longed febrile seizure. Thirty-eight of the 137 children (28%) had a remote sympto-
matic cause for the CSE, 24 (18%) were admitted for an acute symptomatic cause and
15 (11%) were admitted with an acute exacerbation of a pre-existing idiopathic/
cryptogenic epilepsy. Six children had a progressive encephalopathy and no cause was
identified in the remaining 7 of the 137 children (5%). Forty-nine (36%) of the 137
children had pre-existing epilepsy. The mean duration of CSE was 44 min. Forty-nine
(36%) children admitted to PICU who had received a benzodiazepine with either
phenobarbital or phenytoin, required further treatment to terminate the presenting
episode of CSE. Forty-two of these 49 were treated with thiopentone anaesthesia and
the remaining 7 with a continuous infusion of midazolam, successfully terminating
status in all. No child died. Of the 70 children considered to be previously neurolo-
gically and developmentally normal prior to admission, only 1 child demonstrated a
new gross neurological abnormality at the time of latest follow-up. Seven patients
(5%) developed new or de novo epilepsy.
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306 N. Hussain et al.Convulsive (tonic—clonic) status epilepticus (CSE) is
currently defined as a generalised convulsion lasting
30 min or longer, or repeated tonic—clonic convul-
sions recurring over 30 min without recovery of
consciousness between each convulsion.1—4 It is
the most common neurological emergency in child-
hood5 and is life-threatening with risk of neurolo-
gical sequelae.2,4,6
There is no precise figure of the incidence of CSE in
children, which in part, relates to the definition of
status and the population studied. Epidemiological
studies have suggested that four to eight children per
1000 may be expected to experience an episode of
CSE before the age of 15 years,7 and in children with
first seizures, 12% present with CSE as their first
unprovoked seizure.8 A recent systematic review of
the epidemiology of status epilepticus suggested an
incidence of 18—20/10,0000 children per year.9
Approximately 10—25% of children with epilepsy will
have at least 1 episode of CSE.10 Mortality and mor-
bidity due to CSE have declined during the last two
decades. Studies in the 1970s suggested a mortality
rateof3—11%,11,12 comparedwith zero in the last few
years.13,14 More recently, Chin et al. reported a mor-
tality of 3% in 91 children admitted with confirmed
status epilepticus; all deathswere in childrenwith an
acute symptomatic or progressive causeofCSE.15 The
overall reduced mortality may be explained by a
change in the definition of CSE (1 h duration in the
1970s, in contrast to 30 minmore recently) andmore
aggressive treatment of seizures occurring outside
hospital and stricter hospital management of CSE
with clear and time-defined protocols. Neurological
sequelae of CSE (epilepsy, motor deficits, learning
difficulties and behaviour problems) tend to be age-
dependent, occurring in 6% of those over 3 years but
in 29% of those under 1 year of age.11 Important
factors that influence neurological outcome are
reported to include aetiology, duration of CSE and
age.6 Children under 1 year of age more commonly
have an acute symptomatic aetiology, which may
explain the relatively poor outcome in this age group.
Although the outcome of CSE is primarily determined
by its cause, the duration of CSE may also be critical,
with longer durations being associated with a higher
risk of morbidity and mortality.16,17 Delayed treat-
ment of an initial seizure may also increase the
frequency of CSE.6,18 Early seizure termination is
therefore important and this is reflected in the
recently published protocols for treating CSE in chil-
dren.19—22 The current approach is therefore to treat
every child who is in a tonic—clonic convulsion for
more than 5 min as if they were in ‘established CSE’,
to try and prevent the development of persistent
status. Early treatmentmay consequently contribute
to a lower mortality and morbidity.Children in CSE who are admitted to an intensive
care unit (ICU) are likely to reflect the severe end of
the spectrum; this may reflect the underlying cause
or the treatment of the CSE, or both. Consequently,
data from admissions to paediatric intensive care
units (PICUs) for status epilepticus may clarify some
of these issues and may facilitate the development
of strategies to try and reduce the duration of CSE
and its complications. There are few data on chil-
dren with CSE admitted to PICU; two reports pub-
lished over the last 11 years have reported mortality
rates of 6% in 14723 and zero in 186 children;13
however, a recent study found the case fatality of
CSE to be 3% (2—7%).15
The purpose of this retrospective and observa-
tional study was to explore the possible roles of
aetiology, course and short-term neurological out-
come of children with CSE admitted to an ICU. It was
not within the remit of this review to assess the
longer-term developmental, cognitive and beha-
vioural outcome of this population.Patients and methods
The Royal Liverpool Children’s Hospital (Alder Hey)
(RLCH) is one of the largest children’s hospitals in the
UK, serving both a large local population of Liverpool
(300,000) and a tertiary population with a total
population of approximately four million. The hospi-
tal has a 20-bed paediatric intensive care unit. The
diagnosis and demographic characteristics of all
patients admitted to Alder Hey PICU are entered into
a computerised database that includes information
on diagnosis, duration of admission, duration of ven-
tilatory support, condition at discharge, survival and
morbidity. The admission database and discharge
summaries during the period 1st January 1999 to
1st April 2004 were searched to identify all children
admitted with diagnoses of ‘seizure’, ‘epilepsy’,
‘convulsions’, ‘febrile convulsions’, ‘status epilepti-
cus’, ‘encephalopathy’ and ‘coma’. The final criter-
ion for defining the population-base of this study was
all children under the age of 16 years admitted to
PICU at RLCH, between 1st January 1999 and 1st April
2004 with CSE lasting at least 30 min. All available
data, including medical records and intensive care
unit charts were reviewed by hand; this included all
paramedic (ambulance) and accident and emergency
(A + E) records. The review included age, sex, any
pre-existing medical diagnosis, the most reliable
estimate of the actual duration of CSE, including
the time before entering the hospital, and also the
aetiology of status, the treatment received both
before and on admission to hospital, duration of
admission on PICU, and neurological sequelae at
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up. All children with reliable data on CSE were
included in the study. Convulsive status epilepticus
(CSE) was defined as a prolonged generalised tonic—
clonic seizure or a series of tonic—clonic seizures
without recovery of consciousness between seizures
lasting at least 30 min irrespective of whether the
seizure had stopped prior to admission to PICU. The
duration of CSE included both the time prior to
admission through the A + E department and the time
in hospital to terminate the status. Termination of
status was defined on the basis that all clinical signs
of tonic, clonic or tonic—clonic motor activity had
stopped.
Electroencephalographic data were also used (to
define termination of CSE) in those children with
persisting status after admission to PICU. Children
under 1 month of age were excluded because of the
different aetiologies and outcomes of neonatal sei-
zures.24 Children with non-convulsive status were
also excluded because of the difficulty in determin-
ing the precise duration of the seizure activity, its
variable presentations and different outcomes.
Treatment of a tonic—clonic seizure, including
CSE in RLCH is as used nationally in Great Britain.22
This protocol was introduced locally and regionally
in early 2000, approximately 14 months after the
start of this review. Thiopentone and midazolam are
the two most commonly used drugs on PICU to treat
refractory CSE. Refractory CSE was defined as CSE
that had not responded to two doses of benzodia-
zepine and phenytoin or phenobarbitone. The dose
of thiopentone is 4 mg/kg followed by an initial
infusion rate of 3 mg/kg/hour. Midazolam is given
in an initial dose of 0.3 mg/kg followed by an initial
infusion rate of 2—3 mg/kg/min.
Portable 12 or 16-channel EEGs were undertaken
in all children considered to have persisting CSE
when admitted to PICU and were undertaken
between 08.00 and 20.00 h, as there is no overnight
EEG service. Continuous cerebral function analysis
monitoring (CFAM) was unavailable. Blood levels of
antiepileptic drugs (AED) were measured in all chil-
dren with a pre-existing diagnosis of epilepsy and
who were receiving an AED at the time of their
admission to PICU.
The paediatric neurology department at Alder
Hey children’s hospital followed up all patients in
CSE admitted to PICU during the study period. Fol-
low up evaluation comprised of a formal neurologi-
cal examination and a non-standardised assessment
of their development or cognitive function. No for-
mal developmental, cognitive or behavioural assess-
ments (including school reports) were used in the
follow-up evaluation. Neuroimaging and biochem-
ical data are not reported in this study. All childrenwere followed up for a median duration of 1.5 and a
mean of 1.2 years (range, 3 months to 3 years).
Convulsive status epilepticus was classified using
a modification of an earlier classification25 into five
aetiological categories: prolonged febrile convul-
sion (PFC), acute symptomatic (AS), remote symp-
tomatic (RS), idiopathic epilepsy-related (IE-R),
progressive encephalopathy (PE) and unclassified
(U). These were defined as follows:
Prolonged febrile convulsion (PFC)
CSE during a febrile (temperature above 38 8C) ill-
ness in a previously neurologically normal child aged
between 6months and 5 years, and in the absence of
defined central nervous system (CNS) infection.
Acute symptomatic (AS)
CSE in a previous neurologically normal child, within
a week of an identified acute neurological insult
including head trauma, CNS infection, encephalo-
pathy, cerebrovascular disease and metabolic or
toxic derangements.
Remote symptomatic (RS)
CSE in a child with previous neurological abnorm-
ality. This category included children with cerebral
palsy with a febrile illness not of CNS origin and
children with obstructed ventriculo-peritoneal
shunts for post-haemorrhagic hydrocephalus.
Idiopathic, epilepsy-related (IE-R)
CSE in a child with a prior diagnosis of idiopathic or
cryptogenic epilepsy or when the episode of CSE is
the second unprovoked seizure that has led to a
diagnosis of epilepsy.
Progressive encephalopathy (PE)
CSE in a child with progressive neurodegenerative
disease (e.g., late infantile neuronal ceroid lipofus-
cinosis, subacute sclerosing panencephalitis [SSPE],
mitochondrial disease).
Unclassified (C)
CSE that could not be classified into any preceding
category.Statistics
All results are presented in descriptive form.
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Figure 2 Aetiology of CSE according to age.Results
In the 5 years, 137 children aged 1 month to 15 years
were admitted to the PICU with 147 episodes of CSE.
Twenty-eight children (20%) were admitted in the
period prior to the introduction of the local/regional
status epilepticus protocol. Twenty-three of the 137
children (17%) were transfers from other hospitals.
The presenting episode of CSE had stopped in only 19
children on presentation to the A + E department.
These 19 children were admitted to PICU either
because they had required respiratory support in
A + E, or because of the severity of their overall
clinical condition. Sixty-nine patients required
treatment in A + E, which successfully terminated
the presenting episode of status. Fifty-seven of
these 69 children (82%) were subsequently admitted
to PICU for stabilisation and treatment of any under-
lying illness (e.g., meningitis and encephalitis) or
lowGlasgow Coma Scale scores and the remaining 12
children (18%) were admitted because of a recurrent
tonic—clonic seizure following cessation of the
initial CSE in A + E. The remaining 49 patients
required additional treatment on PICU for persisting
CSE that had not responded to treatment in A + E. All
children admitted to PICU following CSE received
ventilatory support.
Aetiology of CSE (Fig. 1)
The most common cause was prolonged febrile con-
vulsion (PFC; 47 of the 137 children, 34%). Thirty-
eight of the 137 children (28%) were admitted fol-
lowing a remote symptomatic (RS) cause. Twenty-
four children (18%) were admitted following an
acute symptomatic episode (including meningitis,
encephalitis, trauma and anoxia). No patient was
found to have hypoglycaemia at the time of pre-
sentation to A + E or on PICU. Fifteen children (11%)
had an IE-R cause, six children (4%) had a PE and in
the remaining 7 of the 137 children (5%), no causeFigure 1 Classification of aetiology of CSE in the 137
children.was identified (U category). In the 38 children with a
remote symptomatic cause of the CSE, 34 had cere-
bral palsy and 34 had epilepsy.
Age and sex (Fig. 2)
The mean age of the study population was 4 years
(median, 2.5 years, S.D., 3 years 7 months; range, 1
month to 15 years). Twenty-eight (20%) patients
were under the age of 1 year and 76 (55%) were
aged 1—5 years. This group represented the largest
subgroup and the majority were classified as PFC
and AS. In children aged 5 years and above, RS and I-
ER were the most common aetiologies. Seventy-four
(54%) of the patients were male.
History of epilepsy
Forty-nine (36%) of the 137 children had a pre-
existing diagnosis of epilepsy. In 34 (69%) this was
symptomatic (28 in the RS and all 6 in the PE group),
in nine idiopathic and in the remaining six, crypto-
genic. All 49 were receiving antiepileptic drugs
(monotherapy in 29, 2 drugs in 12 and 3 drugs in 8
patients). The most commonly used drugs included,
in decreasing order of frequency sodium valproate,
phenobarbitone, lamotrigine, clonazepam, vigaba-
trin and carbamazepine. In the 49 patients with pre-
existing epilepsy, the considered causes for the
exacerbation of the epilepsy resulting in the CSE
included: unknown in 23 (47%), an intercurrent
febrile illness in 18 (37%), a recent change in AED
in six (12%) or possible very poor or no concordance
with antiepileptic medication (based on non-record-
able blood levels of AEDs when measured on pre-
sentation in A + E), in two (4%) patients. Data were
not collected on whether these children had pre-
viously experienced an episode of CSE. In the IE-R
category, all 15 children had a prior diagnosis of
epilepsy (i.e., in none of these patients did the
episode of CSE then lead to a diagnosis of epilepsy).
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dose of rescue medication by their carers prior to
presentation in A + E (rectal diazepam in 38 and
rectal paraldehyde in two; these latter 2 children
had chronic epilepsy and did not usually respond to
rectal diazepam).
Duration of CSE
The mean duration of CSE was 44 (median, 40 and
range, 30—120) min with the shortest duration in
the PFC group (mean, 38 min) and longest in the RS
group (mean, 46 min).
Duration of CSE prior to first medical
treatment
The mean duration of CSE prior to first medical
treatment was 20 (median, 20 and range, 10—
30) min. Eighty-two of the 137 patients (59%) had
received rescue medication administered either by
the child’s carers (40 patients) or by the paramedic
(ambulance) team prior to presentation in A + E (42
patients).
Duration of admission on PICU
The mean duration of stay on PICU of all patients
was 3.5 (median, 2 and range, 1—27) days. The PFC
group required the shortest, and the RS group, the
longest mean period of admission on PICU (1.5
versus 3.4 days, respectively).
PICU course of CSE
No child died. In 19 of the 147 (13%) episodes of CSE,
the child required ventilatory support in A + E
because of respiratory insufficiency rather than
ongoing seizure activity. The median age of these
19 patients was 1.3 years (range, 1 month to 6.5
years). This did not appear to be related to excessive
number or inappropriately high doses of benzodiaze-
pines (based on a review of the parental, paramedic
or A + E records; data not shown). Forty-nine children
of the 137 children (36%) admitted to PICU required
anticonvulsant treatment for ongoing seizure activity
and in over 93% of cases this was the initial, present-
ing episode of status, and not a recurrence of status.
Forty-two of these children were treated with thio-
pentone anaesthesia, successfully terminating the
episode of status in all. The mean duration of thio-
pentone anaesthesia in these cases was 26 h (S.D.
19.4, range 9—72 h). A continuous intravenous infu-
sion of midazolam controlled the status in the
remaining 7 children and was administered for a
minimum of 24 and a maximum of 72 h.Recurrent CSE
Following discharge from hospital and during the
follow-up period, 10 of the 137 children (7%) experi-
enced 1 further episode of CSE and (six in the RS
group, twowith AS and two with PE); no child experi-
encedmore than 1 further episode of CSE necessitat-
ing admission to the PICU during the study period.
Follow-up
The 137 children were followed up for a mean
duration of 1.2 years (median, 1.5 and range, 3
months to 3 years). Of the 70 previously neurologi-
cally normal children, 64 (91%) demonstrated nor-
mal neurological or developmental findings on
discharge from PICU to a general ward. Five of
the remaining six children demonstrated some
impairment of speech, co-ordination or behaviour,
which had resolved at the time of the first neuro-
logical outpatient review following discharge from
hospital. In the one remaining child (in the PFC
group), a hemiplegia was evident at discharge and
this child was subsequently diagnosed with Rasmus-
sen syndrome. Five children in the RS group (all with
a prior background of cerebral palsy), one in the PFC
group and one in the AS group (meningitis), devel-
oped epilepsy. None of the 49 children treated for
refractory CSE developed a new neurological
abnormality but two of these 49 children had devel-
oped de novo epilepsy at follow-up.
Themajority (46 of 47 or 98%) of the children with
prolonged febrile CSE demonstrated normal gross
neurodevelopmental findings at a median period of
1.3 years following discharge from hospital. How-
ever, it must be stressed that none of the children
underwent a formal assessment of their develop-
mental or neuropsychological function. The only
major motor neurological complication was hemi-
plegia, which developed in one previously normal
15-month-old infant with a PFC lasting 40 min and in
whom no obvious focus of infection was identified;
this child was subsequently diagnosed with Rasmus-
sen’s syndrome at 3 years of age.
The most common new neurological problem was
the onset of new (de novo) epilepsy, occurring in 7 of
the 137 (5%) children, which was most prevalent in
the RS group (five patients). There was no correla-
tion between the total duration of CSE or duration of
CSE prior to first medical treatment and the devel-
opment of de novo epilepsy.
Intra-hospital transfers
There were no obvious differences in the demo-
graphic features or outcome between the 23
310 N. Hussain et al.children transferred into PICU from other hospitals
(data not shown). All categories of CSE were repre-
sented in these 23 patients. Three patients required
additional treatment on PICU for persisting status.
One 15-month-old infant developed a hemiplegia
following a PFC (the child with Rasmussen’s
syndrome).
Children treated before and after the
introduction of the local/regional status
epilepticus protocol
No formal comparison was undertaken of the 28
children treated before, and the 109 children trea-
ted after, the introduction of the protocol in terms
of demographic characteristics or outcomes.Discussion
This retrospective review has demonstrated zero
mortality and very lowmorbidity in over 130 children
admittedwith CSE to a tertiary centre PICU. Based on
the current epidemiological data of children with
CSE, and specifically children admitted to an inten-
sive care unit, the confidence intervals (CI) for a
population of this size are approximately 1—3%.
The two most common causes of CSE were febrile
status and a remote symptomatic aetiology. Most
children in the RS group had pre-existing epilepsy.
These results are very similar to those published
recently from Finland.14 In this study of 186 children,
a prolonged tonic—clonic seizure was defined as
lasting longer than 5 min, although the mean dura-
tion of all seizures (42.6 min) was almost identical to
the current study (44 min). No child died in the study
from Finland, four children (2.2%) developed perma-
nent neurological sequelae but 40 children (22%)
developed de novo epilepsy at a mean follow-up of
just over 2 years. In contrast, an earlier 10-year study
from the USA undertaken in 147 children (aged three
days to 18 years) admitted in status to a PICU found
that nine patients (6%) died on PICU, usually due to
the underlying cause of the status, rather than the
status itself.23 In addition, 23 of 114 (20%) previously
normal children had ‘‘some neurological abnormal-
ity’’ that was still evident 1 year after the episode of
status. Epilepsy was cited as themost common cause
of status, occurring in 52 of the 147 patients (35%)
followed by ‘‘atypical febrile convulsions’’ in 21
(14%). This study did not comment on how many
patients developed de novo epilepsy.23 The reasons
for themarkedly discrepant rates of de novo epilepsy
following the CSE between the Finnish (22%) and the
current study (5%) are unclear but may relate to the
accuracy of the diagnosis of ‘epilepsy’ (including thetypes of epilepsy) and how the diagnosis was estab-
lished, and the duration of follow-up. In the seven
patients with de novo epilepsy in the current study, it
was not possible to determine whether the epilepsy
in the five children in the RS group was caused by the
pre-existing underlying brain dysfunction, or second-
ary to the episode of CSE.
The reasons for the zero mortality and low mor-
bidity in thecurrent study, despite ameandurationof
CSE of 44 min, are likely to be multifactorial, includ-
ing the children’s medical and nursing management
on PICU20,26 and an early and aggressive approach to
the management of CSE and its underlying cause
(thereby preventing or reducing any systemic com-
plications). From early 2000, a protocol was intro-
duced for treating a tonic—clonic convulsion
(including CSE) in all A + E departments and wards
in most hospitals in the Mersey (part of the North
West) region (including RLCH) which was identical to
that adopted throughout Great Britain later that
year.22 The most important component of this pro-
tocol was (and is) the fact that all treatment inter-
ventions were (are) prompted by strict, evidence-
based time intervals. Unfortunately, no formal com-
parison was made between the gross neurological
outcome of the 28 patients treated before, and the
109 patients treated after the introduction of this
protocol in early 2000. It is also possible that the
retrospective nature of the current study may not
have accurately identified deviations in the status
protocol. A recent prospective, population-based
study from North London showed that there was
considerable deviation from and failure to follow
the same national protocol; only one in six children
with status epilepticus admitted to their PICU had
been appropriately treated (according to the status
protocol) prior to arrival in the accident and emer-
gency department.27 The authors suggested that this
may have adversely affected the course and outcome
of some of their patients.27 Therewas also no obvious
difference in the demographic characteristics or
gross neurological outcome and incidence of de novo
epilepsy between the 23 children transferred in from
other hospitals and those managed locally; however,
the only child who developed an irreversible neuro-
logical complication (hemiplegia) had been trans-
ferred in from a nearby hospital but it is likely that
she has a progressive condition (Rasmussen’s syn-
drome). It could reasonably have been expected that
children transferred in fromother hospitalsmay have
been in established CSE for longer or may have been
generally sicker (or both) and may also have been
exposed to the potential hazards of an intra-hospital
transfer. The small number of transferred patients
may in part explain the apparent similar outcomes in
the two groups.
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pre-existing epilepsyanda youngage (under 5 years),
in CSE are recognised risk factors associated with
a poorer neuro-developmental outcome.5,21,28,29
Although both acute and remote symptomatic causes
of the CSE were also identified in the current study,
the age at onset, aetiology and duration of CSE were
not found to affect gross neurological outcome. The
reasons for thismay bemultiple, including that in the
current study, most patients’ episode of CSE lasted
less than 60 min and the outcome did not include
formal developmental or neuropsychological assess-
ments. The authors consider that such assessments
would almost certainly have identified significant
cognitive or behaviour difficulties in a number of
these children.
In 19 of the 147 (13%) episodes of CSE, the child
required ventilatory support in A + E because of
respiratory insufficiency rather than ongoing seizure
activity. The North London study suggested that the
risk of respiratory depression appeared to be
greater in those children who received more than
two doses of benzodiazepines and the authors sug-
gested that clinicians should not disregard pre-hos-
pital treatment of CSE when treating the child on
arrival in hospital.27 However, some caution is
required over this suggestion in view of the fact
that 83% of their patients had been inappropriately
treated prior to arrival–—and this could have
included inappropriately high, rather than multiple
doses, of a benzodiazepine. Data from this current
study were not able to confirm or refute the findings
of the North London study.
Over one-third of the children admitted to PICU
required additional anticonvulsant treatment for
continuing CSE. This group could reasonably be
regarded as having ‘refractory’ CSE. The definition
of ‘refractory’ CSE is uncertain but is determined
not only by the duration of CSE, but more impor-
tantly on the lack of response to the use of first-line
anticonvulsants and specifically one (or two) doses
of a benzodiazepine plus the use of either phenytoin
or phenobarbitone. Forty-nine patients met the
criteria for refractory CSE, of whom 42 were treated
with thiopentone anaesthesia and the remaining 7
receivedmidazolam. Treatment was successful in all
49 using clinical and EEG criteria. No patient in this
study proved refractory to either thiopentone or to
midazolam or experienced a recurrence of CSE on
PICU. Importantly, none of these 49 patients had
developed a new neurological problem and only two
had developed de novo epilepsy at latest follow-up;
however, none of these children underwent formal
developmental or neuropsychological evaluation.
Thiopentone is the preferred first line anticonvul-
sant for refractory CSE in the PICU at RLCH andmidazolam is often (but not invariably) used for
children with a diagnosis of chronic epilepsy (often
in association with cerebral palsy or a progressive
encephalopathy), particularly when the child has
had previous episodes of CSE that have responded to
this drug. Thiopentone and midazolam tend to be
the most commonly cited drugs used to treat refrac-
tory or persistent CSE,6,30,31 although other drugs,
including propofol, may also be effective, particu-
larly in adults.32—34 Propofol is not used at RLCH
because of concerns about its use in children and the
risks of the propofol infusion syndrome and death.34
There are obvious and a number of limitations to
this study.Firstly, it is retrospectiveandbasedoncase
note review, although the PICU database is very accu-
rate and likely to ensure complete ascertainment of
all patients admitted to PICU with a diagnosis of
‘seizures, convulsions, fits, febrile convulsions, epi-
lepsy, statusepilepticus’.All childrenadmittedto the
PICU with CSE were discussed with and seen by a
paediatric neurologist to confirm the diagnosis of
CSE and for subsequent management following dis-
chargefromPICUandoutpatient follow-up.Secondly,
although all the patients underwent neurological
examination at follow-up, therewas no formal devel-
opmental or neuropsychological assessment and
school reports were not available. It is therefore
possible, if not likely, that this studyhasnot identified
those children with attention, short-term memory,
planning/processing or other generalised or specific
cognitive difficulties, and particularly in the 49
patients with refractory CSE. Finally, neither contin-
uous cerebral function analysis monitoring (CFAM),
nor daily portable EEGswere undertaken in this study
population, although all patients with refractory CSE
underwent at least one portable 12-lead EEG to con-
firm cessation of electrical seizure activity. However,
it couldbeargued that because thegross neurological
outcome of these children was very favourable, it
would be reasonable to question the role and impor-
tance of CFAM and serial EEG investigations in the
management of, and influence on outcome in this
population although it is recognised that the lack
of formal neuropsychological data may militate
against this argument. It could also be reasoned that,
if more intensive EEG or CFAM data (in demonstrating
continuing electrical seizure activity), had prompted
more aggressive treatment (e.g., attempting to
obtain electrical burst-suppression with higher doses
of thiopentone), this could have resulted in addi-
tional, iatrogenic complications with an increased
risk of both mortality and morbidity.35
In summary, this retrospective review of a large
number of patients has suggested that the current
emergency and intensive care management of CSE
in children appears to be associated with a good
312 N. Hussain et al.outcome, similar to recent data, and represents a
marked improvement when compared to findings
published over 30 years ago. It is particularly
encouraging that none of the 49 patients with
refractory CSE died or suffered a permanent neu-
rological deficit although it is possibly that 1 or more
may have developed developmental, cognitive or
behavioural sequelae as a direct result of the status
and that have not been identified in this study. It
would be important to undertake a prospective
study on all children admitted to PICU in not only
CSE but also refractory CSE, and to evaluate their
cognitive and behavioural outcomes using standar-
dised neuropsychological assessments. It would also
be useful to document the incidence and types of de
novo epilepsy developing in this population.Conflict of interest and financial
disclosure
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